How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?

While cirrhosis patients are considered high risk for infection and related acute-on-chronic liver failure, I would not consider it an absolute C/I for biologics if they have active RA and need escalation of treatment. Data on infection outcomes in cirrhosis patients on biologics is limited.

I agree...